-
EP4346907
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4346907
| EP4346907 - IMPROVED IMMUNOGLOBULIN I [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 08.03.2024 Database last updated on 18.11.2024 | |
| Former | The international publication has been made Status updated on 02.12.2022 | Most recent event Tooltip | 26.07.2024 | Change: Validation states | published on 28.08.2024 [2024/35] | 26.07.2024 | Change - extension states | published on 28.08.2024 [2024/35] | Applicant(s) | For all designated states Transmab Pty Ltd c/o Level 4 100 Albert Road South Melbourne, VIC 3205 / AU | [2024/15] | Inventor(s) | 01 /
DUBLJEVIC, Valentina Melbourne, Victoria 3205 / AU | 02 /
CAMPBELL, James Melbourne, Victoria 3205 / AU | [2024/15] | Representative(s) | Boult Wade Tennant LLP Salisbury Square House 8 Salisbury Square London EC4Y 8AP / GB | [2024/15] | Application number, filing date | 22809964.4 | 25.05.2022 | [2024/15] | WO2022AU50503 | Priority number, date | AU20210901567 | 25.05.2021 Original published format: AU 2021901567 | [2024/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022246510 | Date: | 01.12.2022 | Language: | EN | [2022/48] | Type: | A1 Application with search report | No.: | EP4346907 | Date: | 10.04.2024 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.12.2022 takes the place of the publication of the European patent application. | [2024/15] | Search report(s) | International search report - published on: | AU | 01.12.2022 | Classification | IPC: | A61K47/68, A61K49/00, G01N33/533, G01N33/534, A61K39/00, C07K16/44, A61K51/10, A61K9/00, A61P35/00 | [2024/15] | CPC: |
A61P35/00 (EP,AU,US);
A61K47/6801 (AU);
A61K47/6843 (US);
A61K47/6835 (EP);
A61K47/6877 (AU);
A61K49/0002 (US);
A61K49/0058 (EP,AU);
A61K51/1018 (US);
A61K51/1096 (EP,AU);
C07K16/44 (EP,AU);
G01N33/533 (AU);
G01N33/534 (AU);
A61K2039/505 (EP,AU);
A61K9/0019 (EP,AU);
C07K2317/56 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/15] | Title | German: | VERBESSERTES IMMUNGLOBULIN I | [2024/15] | English: | IMPROVED IMMUNOGLOBULIN I | [2024/15] | French: | IMMUNOGLOBULINE I AMÉLIORÉE | [2024/15] | Entry into regional phase | 07.12.2023 | National basic fee paid | 07.12.2023 | Search fee paid | 07.12.2023 | Designation fee(s) paid | 07.12.2023 | Examination fee paid | Examination procedure | 07.12.2023 | Examination requested [2024/15] | 08.07.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 26.04.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2019018428 (NUCLEUS THERAPEUTICS PTY LTD [AU], et al); | [Y]WO2019018426 (NUCLEUS THERAPEUTICS PTY LTD [AU], et al); | [Y]WO2019152806 (UNIV YALE [US]); | [A]WO2021042060 (UNIV YALE [US]); | [Y]WO2021077070 (UNIV YALE [US]); |